Arrowstreet Capital
ASMB icon

Arrowstreet Capital’s Assembly Biosciences ASMB Stock Holding History

Arrowstreet Capital’s Portfolio ASMB Stock Details ASMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-39,446
Closed -$1.09M – 1906
2026
Q1 		$1.09M Buy
39,446
+1,634
+4% +$46.6K ﹤0.01% 1538
2025
Q4 		$1.29M Buy
+37,812
New +$1.22M ﹤0.01% 1503

Other funds holding ASMB

GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PHP
Parkman Healthcare Partners Stamford, Connecticut $977M AUM 110.37% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Arrowstreet Capital's ASMB Position: Q2 2026 in Review

Arrowstreet Capital sold out of Assembly Biosciences (ASMB) in Q2 2026, closing a stake of 39,446 shares — an estimated $1.09M sold.

Arrowstreet Capital first reported a position in ASMB in Q4 2025 and held it in 2 quarters. The position peaked at $1.29M in Q4 2025. 93 funds tracked by Wall St. Rank hold ASMB as of Q2 2026.

  • Arrowstreet Capital reported no remaining Assembly Biosciences position as of Q2 2026 after selling out during the quarter.
  • Arrowstreet Capital sold 39,446 Assembly Biosciences shares in Q2 2026, an estimated $1.09M.
  • Arrowstreet Capital first reported a position in Assembly Biosciences in Q4 2025 and held it in 2 quarters.
  • Arrowstreet Capital's Assembly Biosciences position peaked at $1.29M in Q4 2025.
  • 93 funds tracked by Wall St. Rank held Assembly Biosciences as of Q2 2026.

Based on Arrowstreet Capital's 13F filing for Q2 2026, filed 13 Aug 2026.